Fenofibrate Induced Nephrotoxicity and Paradoxical Low HDLC- A Boon or Bane?: A Review

A. S. V. Prasad *

Department of Intern Medicine, GITAM Dental Collage, GITAM University Compound, Rushikonda, Visakhapatnam, Andhra Pradesh, India.

*Author to whom correspondence should be addressed.


Abstract

Fenofibrate is the most common drug prescribed to treat atherogenic dyslipidaemia. The nephrotoxicity of fenofibrate, as characterised by the increased Serum Creatinine (SCr) and reduced estimated glomerular filtration rate (eGFR), though reported in literature, it's clinical awareness, and it's implications, seem to be low. Also reported is the paradoxical Low level of High-density lipoprotein cholesterol (HDLC) during fenofibrate therapy, as against the expected rise, as an isolated event and, in conjunction with the raised SCr. Perhaps such association occurred, in a small subset of cases of fenofibrate induced nephrotoxicity or it may be due to lack of awareness about the association or the association being overlooked, these might be the reasons for the paucity of reporting the same, in the literature. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, and the Action to Control Cardiovascular Risk in Diabetes (ACCORD Lipid Study), it is confirmed that, the SCr levels decreased, eGFR improved and HDLC levels are raised on cessation of the fenofibrate therapy. The cause and effect is, thus proved. The CKD, triglyceredemia and the low HDLC. Each of the three, are know individual risk factors for cardiovascular disease (CVD). It would be the concern of any body, treating atherogenic dislipidema, as to whether to expose the patient to the risks of possible renal damage and the risks of low HDLC, in treating hypertriglyceridemia, with fenofibrate. It is imperative that these concerns, if any, be resolved. Awareness of fenofibrate causing the raised Scr and reduced eGFR, is essential for avoiding wrong diagnosis and treatment of an iotrogenic cause. Apart from the dark side of fenofibrate therapy, umpteen number of benefits of fenofibrate therapy are reported. Intriguingly, the greatest benefits are seen in those who experienced the most severe adverse effects mentioned above. Hence is the justification for the dilemma expressed in the tittle. A brief review of all the issues concerned, including the present status of the fenofibrate therapy, is being reviewed in this article.

Keywords: Creatinine, fenofibrate, nephrotoxicity, triglycerides, estimated glomerular filtration rate, HDL cholesterol


How to Cite

Prasad, A. S. V. 2022. “Fenofibrate Induced Nephrotoxicity and Paradoxical Low HDLC- A Boon or Bane?: A Review”. Asian Journal of Research in Nephrology 5 (1):94-106. https://journalajrn.com/index.php/AJRN/article/view/49.

Downloads

Download data is not yet available.

References

Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: What have we learned in the past 40 years. Pharmacotherapy. 2007;27:412–424.

[PubMed] [Google Scholar]

Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis. 2010;210:35–40. [PubMed] [Google Scholar]

Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: A systematic review. Am J Med. 2009;122:962.e1–962.e8. [PubMed] [Google Scholar]

Jacobson TA, Miller M, Schaefer EJ. Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther. 2007;29:763–777. [PubMed] [Google Scholar]

Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: Its etiology, effects and treatment. CMAJ. 2007;176:1113–1120. [PMC free article] [PubMed] [Google Scholar]

Rossner S, Oro L. Fenofibrate therapy of hyperlipoproteinaemia: A dose-response study and a comparison with clofibrate. Atherosclerosis. 1981;38:273–282. [PubMed] [Google Scholar]

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005;366:1849–1861. [PubMed] [Google Scholar]

Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, et al. (ACCORD Study Group.). Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574. [PMC free article] [PubMed] [Google Scholar

Lageder H. Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia. Wien Klin Wochenschr. 1980;92:95–101.

[PubMed [Google Scholar]

Dick TB, Marples J, Ledermann HM, Whittington J. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia. Curr Med Res Opin. 1981;7:489–502. [PubMed] [Google Scholar]

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005;366:1849–1861. [PubMed] [Google Scholar]

ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–1574. [PMC free article] [PubMed] [Google Scholar]

Broeders N, Knoop C, Antoine M et al. Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only in- nocuous agent? Nephrol Dial Transplant. 2000;15:1993-9.

Lipscombe J, Lewis GF, Cattran D, et al. Deterioration in renal function associ- ated with fibrate therapy. Clin Nephrol. 2001;55:39-44.

Ritter JL, Nabulsi S. Fenofibrate-induced elevation in serum creatinine. Pharmaco-therapy. 2001;21:1145-9.

Paul S, Mohan V. Fenofibrate can increase serum creatinine levels in renal insufficiency. J Assoc Physicians India. 2006;54:337. Letter.

McQuade CR, Griego J, Anderson J, et al. Elevated serum creatinine levels associated with fenofibrate therapy. Am J Health-Syst Pharm.

Attridge RL, Linn WD, Ryan L et al. Evaluation of the incidence and risk factors for development of fenofibrate- associated nephrotoxicity. J Clin Lipidol. 2012;6: 19-26.

Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of cre-atinine. Nephron. 2002;92:536-41. .

Ansquer JC, Dalton RN, CaussEffect of fenofibrate on kidney function: A 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008;51:904-13

Ritter JL, Nabulsi S. Fenofibrate-induced elevation in serum creatinine. Pharmaco-therapy. 2001; 21:1145-9.22. Bonds DE, Craven TE, Buse J et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with Type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia. 2012;55:1641–1650.

Ansquer J-C, Dalton RN, Causse E, Crimet D, Malicot KL, Foucher C. Effect of fenofibrate on kidney function: A 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008;51: 904–913.

Forsblom C, Hiukka A, Leinonen E, Sundvall J, Groop PH, Taskinen M-R. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: FIELD Helsinki Substudy. Diab Care. 2010;33:215–220.

Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–2093.

Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in Type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. 2005; 45:485–493.

Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905–910.

The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial. Lancet. 2005; 366:1849–1861.

The Accord Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–157430.

Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatinemia by increasing metabolic production of creatinine. Nephron. 2002; 92:536–541.

Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatinemia by increasing metabolic production of creatinine. Nephron. 2002; 92:536–541. [Google Scholar]

Balakumar P, Kadian S, Mahadevan N. Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? Pharmacol. Res. 2012;65:430–436.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.

[Google Scholar]

Broeders N, Knoop C, Antoine M, et al. Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only in-nocuous agent? Nephrol Dial Transplant. 2000;15:1993-9.

Shahinfar S, Dickson T, Zhang Z, Keane WF, Brenner BM, for the renaal Investigators. Baseline predictors of end-stage renal disease risk in patients with Type 2 diabetes and nephropathy: new lessons from the RENAAL Study. Kidney Int. 2005;67:S48–S51.

Paul S, Mohan V. Fenofibrate can increase serum creatinine levels in renal insuf-ficiency. J Assoc Physicians India. 2006; 54:337. Letter.

Ritter JL, Nabulsi S. Fenofibrate-induced elevation in serum creatinine. Pharmaco-therapy. 2001;21:1145-9.

Lipscombe J, Lewis GF, Cattran D, et al. Deterioration in renal function associ-ated with fibrate therapy. Clin Nephrol. 2001; 55:39-44.

Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of cre- atinine. Nephron. 2002;92:536-41.

Forsblom C, Sundvall J, Hiukka A, et al. Effects of long-term fenofibrate treat-ment on markers of renal function in type 2 diabetes: the FIELD Helsinki sub-study. Diabetes Care. 2010;33:215-20.

Ansquer JC, Dalton RN, Causse E, et al. Effect of fenofibrate on kidney function: A 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008; 51:904-13.

McQuade CR, Griego J, Anderson J et al. Elevated serum creatinine levels as- sociated with fenofibrate therapy. Am J Health-Syst Pharm. 2008;65:138-41.

D, Dembinski T, Friesen MH. Iatrogenic severe depression of high-density lipoprotein cholesterol. J Clin Pharmacol. 2009;49:865–871 [PubMed] [Google Scholar]

Peter E. Linz, Laura C. Lovato, Marshall B. Elam paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: The accord lipid trial. Diabetes Care. 2014;37(3):686–693.

Published online 2014 Feb 11.

DOI: 10.2337/dc13-0790

Venero CV, Thompson PD, Fernandez AB. Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate. Am J Med. 2008;121:e3–e4

[PubMed] [Google Scholar]

Giuliana Mombelli, Franco Pazzucconi, Alighiero Bondioli, et al Paradoxical decrease in high‐density lipoprotein cholesterol with fenofibrate: A quite rare phenomenon indeed .cardiovascular therapeutics. 2010;28(3):153-60.

DOI: 10.1111/j.1755-5922.2009.00121.

Mymin D, Dembinski T, HH M, et al. The Journal of Clinical Pharmacology. 2013; 49(7):865-871.

Available:https://doi.org/10.1177/0091270009335766

McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep. 2008;10(5):386-90.

DOI: 10.1007/s11883-008-0060-9. PMID: 18706279.

Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–2093.

Agouridis AP, Kostapanos MS, Tsimihodimos V, et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or omega-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int. J. Clin. Pract. 2012;66:843–853.

Jong MC, Hofker MH, Havekes LM. Role of apoCs in lipoprotein metabolism:functional differences between apoC1, apoC2, and apoC3. Arterioscler. Thromb. Vasc. Biol. 1999;19:472–484.

Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis. 2010;210:35–40.

[PubMed] [Google Scholar]

Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med. 2009;12* Review of the possible mechanisms of PPAR-α activation in the treatment of diabetic kidney disease.

Ting RD, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with Type 2 diabetes and renal impairment: the FIELD Study. Diabetes Care. 2012;35: 218–225.

Davis T, Ting R, Best J et al. Effects of fenofibrate on renal function in patients with Type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011;54:280–290.

* Clinical paper of a large randomized controlled trial examining the renal effects of fenofibrate in Type 2 diabeting RD, Keech AC, Drury PL et al. Benefits and safety of long-term fenofibrate therapy in people with Type 2 diabetes and renal impairment: the FIELD Study.

Agouridis AP, Kostapanos MS, Tsimihodimos V, et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or omega-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int. J. Clin. Pract. 2012;66:843–853.

Shahinfar S, Dickson T, Zhang Z, Keane WF, Brenner BM, for the RENAAL Investigators. Baseline predictors of end-stage renal disease risk in patients with Type 2 diabetes and nephropathy: New lessons from the RENAAL Study. Kidney Int. 2005;67:S48–S51.

Ru-Dee Ting; Anthony Keech Fenofibrate and Renal Disease Clinical Effects in Diabetes Clin Lipidology. 2013;8(6):669-680 14.Keating GM, Croom KF. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and Type 2 diabetes mellitus. Drugs. 2007;67:121–153.

Yokoyama H, Oishi M, Kawai K, Sone H. Japan diabetes clinical data management study group. Reduced GFR and microalbuminuria are independently associated with prevalent cardiovascular disease in Type 2 diabetes: JDDM study 1 Diabet Med. 2008;25(12): 1426-32.

DOI: 10.1111/j.1464-5491.2008.02592.x. PMID: 19046241.

Adkins J C, Faulds D,"Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia", Drugs. 1997;54:615-633.8.

Farnier M, Bonnefous F, Debbas N, Irvine A, "Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia", Archives of Internal Medicine. 1994;154:441-449.. cardiovascular Pharmacology. 1996; 27:563 570.

Crossref| PubMed

Hottelart C, El Esper N, Rose F, et al. Fenofibrate increases creatininemia by increasing metabolic production of cre- atinine. Nephron. 2002;92:536-41.

Neve BP, Corseaux D, Chinetti G, et al. PPARalpha agonists inhibit tissue factor [expression in human monocytes and macrophages. Circulation. 2001;6;103(2): 207–212. [PubMed] [Google Scholar]

Marx N, Mackman N, Schonbeck U, et al. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation. 2001;103(2):213–219. [PubMed] [Google Scholar]

Mangan S, Clancy P, Golledge J. Modulation of endothelial cell thrombomodulin by PPAR ligands--variation according to environment. Thromb Res. 2008;121(6):827–834. [PMC free article] [PubMed] [Google Scholar]

Okopien B, Cwalina L, Lebek M, et al. Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia. Int J Clin Pharmacol Ther. 2001;39(12):551–557. [PubMed] [Google Scholar

Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: An overview. Eur. J. Clin. Invest. 2013;43:522–531.

Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Current Opinion In Lipidology 1999;10:151-159

Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. Journal of Biological Chemistry. 1998;273:32,833-32,841.

Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart J-C, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative crosstalk with transcription factors NF-kappa B and AP-1. J. Biol. Chem. 1999;274:32,048-32,054.

Marx N, Sukhova G K, Collins T, Libby P, Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999;99: 3,125-3,1131.l.

Staels B, Koenig W, Habib A, Merval R, Lebret M,Torra I P, Delerive P, Fadel A, Chinetti G, Fruchart J C, Najib J, Maclouf J,Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators", Nature. 1998;393:790-793.

Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am. J. Med. 2002;112:275-280.

Despres JP, Lemieux I, Pascot A, Almeras N, Dumont M, Nadeau A, Bergeron J. Prud'homme D,"Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome. Arteriosclerosis, Thrombosis & Vascular Biology. 2003;23: 702-703.

Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans. Atherosclerosis. 2010;210:35–40.

[PubMed] [Google Scholar]

Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med. 2009;122:962.e1–962.e8.

[PubMed] [Google Scholar

Diabetes Atherosclerosis intervention study investigators. Effect of fenofibrate on progression of coronary-artery disease in Type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357: 905–910.

Park CW, Zhang Y, Zhang X, et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int. 2006;69:1511–1517.

Kostapanos MS, Florentin M, Elisaf MS. Fenofibrate and the kidney: An overview. Eur. J. Clin. Invest. 2013;43:522–531.

Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin. Nephrol. 2001;55:39–44.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.

[PubMed] [Google Scholar]

McAuley KA, Williams SM, Mann JI, Walker RJ, Lewis-Barned NJ, Temple LA, et al. Diagnosing insulin resistance in the general population. Diabetes Care. 2001; 24:460–4. [PubMed] [Google Scholar]

Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology. 2003;42:321-325.

Uetake D, Ohno I, Ichida K, et al. Effect of fenofibrate on uric acid metabolism and urate transporter 1. Intern Med. 2010;49(2):89–94. [PubMed] [Google Scholar5.

Chen H, Sullivan G, Yue LQ, Katz A, Quon MJ. QUICKI is a useful index of insulin sensitivity in subjects with hypertension. Am J Physiol Endocrinol Metab. 2003;284:E804–12. [PubMed] [Google Scholar]

Prasad ASV. An investigation into the molecular mechanism of inverse relationship between S. Creatinine and HDL-C in CKD. Asian Journal of Research in Nephrology. 2022;5(2):30-39.

Available:https://journalajrn.com/index.php/AJRN/article/view/4

Glaysher J, Van Heyningen C. Paradoxical decrease in high density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy. The British Journal of Diabetes & Vascular Disease. 2007;7(6):295-7.

Foucher C, Brugere L, Ansquer JC. Fenofibrate, homocysteine and renal function. Current Vascular Pharmacology. 2010;8(5):589-603.